EOLS

RxSight's After-Hours Surge: RxSight shares jumped 18.1% after reporting a wider net loss and a 14% revenue decline, but improved its full-year revenue guidance and gross margin outlook.

Penumbra's Strong Performance: Penumbra's stock rose 16.4% following a strong Q3 with increased net income and revenue, along with a raised full-year revenue forecast.

Evolus Continues Gains: Evolus saw a 13.5% increase in after-hours trading after narrowing its net loss and reporting revenue growth, while reaffirming its full-year revenue guidance.

Modest Growth for Other Companies: CVRx and Cytek Biosciences also experienced after-hours gains, with CVRx reporting a slight improvement in losses and revenue growth, while Cytek reaffirmed its future revenue guidance despite a net loss.

Partnership Announcement: Evolus, Inc. has appointed Dr. Benjamin Eskenazi as the lead consultant for the national launch of their new Evolysse™ hyaluronic acid filler line, emphasizing their commitment to patient safety and provider education.

Innovative Technology: The Evolysse™ fillers, utilizing Cold-X™ technology, are the first major advancement in hyaluronic acid dermal fillers in a decade, promising longer-lasting and natural-looking results, with FDA approval recently granted for Evolysse™ Form and Evolysse™ Smooth.

Stock Options and RSUs Granted: Evolus, Inc. has granted stock options and restricted stock units (RSUs) to newly hired employees, including 143,403 shares and 104,603 RSUs to the new Chief Financial Officer, Tatjana Mitchell, as part of their 2023 Inducement Incentive Plan.

Vesting and Exercise Details: The stock options have a 10-year term and vest over four years, with specific vesting schedules for both non-executive employees and Ms. Mitchell, who has different terms for her RSUs.